GlassScriptPhysician profile
Erin J Fish
NPI 1073554069
$4,581.80
in general payments reported to CMS, 2019-2025
37 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.58 · 2020: $294 · 2021: $311 · 2022: $141 · 2023: $883 · 2024: $1,464 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.55 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,029.28 | 2021-2025 | |
| Pfizer INC. | $432.15 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.75 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $407.95 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $317.44 | 2020-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.33 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $162.53 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $152.24 | 2023-2025 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $146.15 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $137.69 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Lundbeck LLC | $130.28 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $117.70 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $102.42 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $84.49 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.23 | 2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.65 | 2020-2023 | |
| Exact Sciences Corporation | $63.32 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $62.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $61.89 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $47.40 | 2024 | |
| Almatica Pharma LLC | $42.76 | 2023-2024 | Loreev Xr |
| Astellas Pharma US INC | $38.91 | 2023-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $37.00 | 2020-2025 | Austedo Xr |
| Ironwood Pharmaceuticals, INC | $35.13 | 2020 | |
| Merck Sharp & Dohme LLC | $31.91 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $22.91 | 2025 | Shingrix |
| Grifols USA, LLC | $19.14 | 2024 | Prolastin-C Liquid |
| Amgen INC. | $18.95 | 2020 | |
| Insulet Corporation | $18.89 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $18.74 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $18.45 | 2020 | |
| Sanofi Pasteur INC. | $18.07 | 2020 | |
| Viatris Specialty LLC | $17.66 | 2025 | Yupelri |
| Dexcom, INC. | $15.82 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2025 | Trintellix |
| Seqirus USA INC | $15.67 | 2025 | Flucelvax, Fluad |
| Medtronic, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.